Infliximab has been found an efficacious treatment in moderate to severe hidradenitis suppurativa (HS), according to findings from a review and meta-analysis published in Dermatologic Therapy.
Investigators sought to provide a review of the efficacy of infliximab in treating HS.
They directed a systematic review and meta-analysis in September, 2021 of 19 articles (6 prospective, 13 retrospective studies) in English with 5 or more HS patients each from MEDLINE and EMBASE databases that included 314 patients in total with HS, of whom 299 had severity data available (moderate to severe). Outcome measures were clinician reported in 16 of the studies, and patient reported or patient plus clinician reported in the remaining 3 studies. Only 5 of these studies were randomized controlled trials (RCTs) or open-label trials.
For patients with HS treated with infliximab the pooled response rate was 83% (95% CI, 0.71-0.91). “Serious adverse events” (AEs) occurred at a rate of 2.9%, a single report each of anaphylactic shock, death from lung malignancy, metastatic squamous cell carcinoma, Hodgkin lymphoma, sepsis, lupus, tuberculosis, and grade 3 multifocal motor neuropathy. Most common AEs were infusion reaction (2.9%) and nonserious infections (13.2%).
Study limitations include heterogeneity between studies and the small number of prospective studies. All but 1 study originated in Europe or North America, possibly limiting generalizability, and reviewers were unable to compare response rates.
They concluded that infliximab may be an effective treatment for HS, but “Larger RCTs are needed to explore the comparative efficacy of infliximab in HS against other biologics as well as the efficacy of infliximab when combined with other treatment modalities.”
Disclosure: Several study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Shih T, Lee K, Grogan T, De DR, Shi VY, Hsiao JL. Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis. Dermatol Ther. Published online July 5, 2022. doi:10.1111/dth.15691